Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolute 303: Daraxonrasib ± Gemcitabine + Nab-paclitaxel in Metastatic Pancreatic Adenocarcinoma
jRCT2071260040Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Jun 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of daraxonrasib in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Revolution Medicines. Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Started Jun 2026; status: recruiting.
02
Drugs
daraxonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2071260040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260040.